Alalevonadifloxacin mesylate

N/A

Report date: 2026/03/04 20:01:44
NMEQIDP

Base Information

Drug NameAlalevonadifloxacin mesylate
Drug Alias NamealalevonadifloxacinEmrok OWCK-177 prodrug (MRSA infection)WCK-2349Nadifloxacin prodrug +[7] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Quinolone antibioticsSmall molecules > Prodrug
Mechanisms of ActionTopoisomerase IV inhibitorsBacterial DNA gyrase inhibitors
TargetsBacterial DNA gyraseTopoisomerase IV
Therapy Area/IndicationsHeart DiseasesHepatic InsufficiencyGram-Positive Bacterial Infections
Global Approved IndicationsGram-Positive Bacterial Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2019/12/13
Country/TerritoryUnited StatesIndia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesWockhardt Bio Ag
China Registration ClassN/A

Develop Information

Active CompaniesWockhardt Ltd
Inactive CompaniesN/A
Active IndicationsGram-Positive Bacterial Infections
Inactive IndicationsHeart DiseasesHepatic Insufficiency

Other Information

ATC CodeJ01MA24
Related LinksN/A